<DOC>
	<DOCNO>NCT00213473</DOCNO>
	<brief_summary>aim SACHA study appreciate prevalence , evolution follow-up , treatment response patient acquire hemophilia biological clinical data . Inclusion criterion factor VIIIc 30 % associate presence Facgteur VIII inhibitor ( titer &gt; 1 u Bethesda . Clinical biologival data obtain Day 0 ( soon possible 1 , 3 , 6 12 months.Informations notify co-investigators help two french medical society ( Internal medicine , french haemostasis thrombosis society .</brief_summary>
	<brief_title>Prospective Clinical Biological Follow-up Acquired Haemophilia : SACHA Study</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Factor VIIIc &lt; 30 % Factor VIII inhibitor &gt; 1 u Bethesda absence sign consent , haemophilia A</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>acquire haemophilia</keyword>
</DOC>